XORTX Therapeutics Ownership
| XRTX Stock | USD 1.21 0.02 1.68% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 2.4 M | Current Value 2.9 M | Avarage Shares Outstanding 1.2 M | Quarterly Volatility 2.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
XORTX |
XORTX Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 1.8. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XORTX Therapeutics has Price/Earnings (P/E) ratio of 170.67. The entity last dividend was issued on the January 31, 2014. The firm had 1:9 split on the 14th of November 2023. XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. Xortx Therapeutics is traded on NASDAQ Exchange in the United States. For more information please call Allen Davidoff at 403 455 7727 or visit https://www.xortx.com.Besides selling stocks to institutional investors, XORTX Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different XORTX Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align XORTX Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
XORTX Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of XORTX Therapeutics are currently held by insiders. Unlike XORTX Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against XORTX Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of XORTX Therapeutics' insider trades
XORTX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XORTX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XORTX Therapeutics backward and forwards among themselves. XORTX Therapeutics' institutional investor refers to the entity that pools money to purchase XORTX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-09-30 | 18.8 K | Advisor Group Holdings, Inc. | 2024-09-30 | 1.2 K | Royal Bank Of Canada | 2024-09-30 | 672 | Hartland & Co | 2024-09-30 | 277 | Jpmorgan Chase & Co | 2024-09-30 | 254 | Tower Research Capital Llc | 2024-09-30 | 84.0 | Bank Of Montreal | 2024-06-30 | 0.0 | Bmo Capital Markets Corp. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XORTX Therapeutics Outstanding Bonds
XORTX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XORTX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XORTX bonds can be classified according to their maturity, which is the date when XORTX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.